| Literature DB >> 28591637 |
Jinrang Kim1, Haruka Okamoto1, ZhiJiang Huang2, Guillermo Anguiano2, Shiuhwei Chen2, Qing Liu2, Katie Cavino1, Yurong Xin1, Erqian Na1, Rachid Hamid1, Joseph Lee1, Brian Zambrowicz1, Roger Unger3, Andrew J Murphy1, Yan Xu2, George D Yancopoulos1, Wen-Hong Li4, Jesper Gromada5.
Abstract
Glucagon supports glucose homeostasis by stimulating hepatic gluconeogenesis, in part by promoting the uptake and conversion of amino acids into gluconeogenic precursors. Genetic disruption or pharmacologic inhibition of glucagon signaling results in elevated plasma amino acids and compensatory glucagon hypersecretion involving expansion of pancreatic α cell mass. Recent findings indicate that hyperaminoacidemia triggers pancreatic α cell proliferation via an mTOR-dependent pathway. We confirm and extend these findings by demonstrating that glucagon pathway blockade selectively increases expression of the sodium-coupled neutral amino acid transporter Slc38a5 in a subset of highly proliferative α cells and that Slc38a5 controls the pancreatic response to glucagon pathway blockade; most notably, mice deficient in Slc38a5 exhibit markedly decreased α cell hyperplasia to glucagon pathway blockade-induced hyperaminoacidemia. These results show that Slc38a5 is a key component of the feedback circuit between glucagon receptor signaling in the liver and amino-acid-dependent regulation of pancreatic α cell mass in mice.Entities:
Keywords: Slc38a5; amino acid transporter; glucagon; glucagon receptor; glucagon receptor knockout; hyperaminoacidemia; mTORC1; pancreatic alpha cell; proliferation
Mesh:
Substances:
Year: 2017 PMID: 28591637 PMCID: PMC8206958 DOI: 10.1016/j.cmet.2017.05.006
Source DB: PubMed Journal: Cell Metab ISSN: 1550-4131 Impact factor: 27.287